In fact, it was shown that TNFR2 agonistic antibody Y9 could inhibit tumor growth by acting directly on CD8 CTLs in tumors and stimulating their activation and expansion in murine cancer models (27). This evidence concerns the gene TNFRSF1B and cancer.